High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 Inhibition

被引：0

作者：

Ugurel, S. ^{[1
]}

Schadendorf, D. ^{[1
]}

Sucker, A. ^{[1
]}

Schramm, S. ^{[2
]}

Utikal, J. ^{[3
]}

Pfoehler, C. ^{[4
]}

Herbst, R. ^{[5
]}

Schilling, B. ^{[6
]}

Blank, C. ^{[7
]}

Becker, J. C. ^{[1
,8
]}

Paschen, A. ^{[1
]}

Zimmer, L. ^{[1
]}

Livingstone, E. ^{[1
]}

Horn, P. A. ^{[2
]}

Rebmann, V. ^{[2
]}

机构：

[1] Univ Klinikum Essen, Klin Dermatol Venerol & Allergol, Essen, Germany

[2] Univ Klinikum Essen, Transfus Med, Essen, Germany

[3] Univ Klinikum Mannheim, Hautklin, Mannheim, Germany

[4] Univ Saarland, Hautklin, Homburg, Germany

[5] Helios Klinikum Erfurt, Hautklin, Erfurt, Germany

[6] Univ Klinikum Wurzburg, Hautklin, Wurzburg, Germany

[7] Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands

[8] German Consortium Translat Canc Res DKTK, Translat Skin Canc Res, Heidelberg, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

FV09

引用

页码：7 / 7

页数：1

共 50 条

[1] PD-1 and PD-L1 antibodies for melanoma
Tsai, Katy K.
Zarzoso, Ines
Daud, Adil I.
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116
[2] Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
Ugurel, S.
Schadendorf, D.
Horny, K.
Sucker, A.
Schramm, S.
Utikal, J.
Pfoehler, C.
Herbst, R.
Schilling, B.
Blank, C.
Becker, J. C.
Paschen, A.
Zimmer, L.
Livingstone, E.
Horn, P. A.
Rebmann, V
[J]. ANNALS OF ONCOLOGY, 2020, 31 (01) : 144 - 152
[3] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, Jie
Gao, Zhitao
Li, Xiang
Dong, Liang
Han, Weidong
Nie, Jing
[J]. ONCOTARGET, 2017, 8 (66) : 110693 - 110707
[4] Expression of PD-L1 and PD-1 in conjunctival melanoma
Cao, Jinfeng
Richards, Kate
Jordanova, Ekaterina S.
Arinkovic, Marina
Hurkmans, Daan
van Duinen, Sjoerd G.
van der Velden, Pieter A.
Jager, Martine J.
[J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[5] A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Girault, Isabelle
Adam, Julien
Shen, Shensi
Roy, Severine
Brard, Caroline
Faouzi, Sara
Routier, Emilie
Lupu, Jeremy
Warren, Sarah
Sorg, Kristina
Ong, SuFey
Morel, Pascale
Scoazec, Jean-Yves
Vagner, Stephan
Robert, Caroline
[J]. CLINICAL CANCER RESEARCH, 2022, 28 (03) : 518 - 525
[6] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares
Claire Battin
Sabrina Jutz
Judith Leitner
Christine Hafner
Joshua Tobias
Ursula Wiedermann
Michael Kundi
Gerhard J. Zlabinger
Katharina Grabmeier-Pfistershammer
Peter Steinberger
[J]. Scientific Reports, 9
[7] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Linhares, Annika De Sousa
Battin, Claire
Jutz, Sabrina
Leitner, Judith
Hafner, Christine
Tobias, Joshua
Wiedermann, Ursula
Kundi, Michael
Zlabinger, Gerhard J.
Grabmeier-Pfistershammer, Katharina
Steinberger, Peter
[J]. SCIENTIFIC REPORTS, 2019, 9 (1)
[8] Biomarkers of response to PD-1/PD-L1 inhibition
Vareki, Saman Maleki
Garrigos, Carmen
Duran, Ignacio
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124
[9] PD-1/PD-L1 inhibitors
Sunshine, Joel
Taube, Janis M.
[J]. CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
[10] PD-1/PD-L1 in disease
Kuol, Nyanbol
Stojanovska, Lily
Nurgali, Kulmira
Apostolopoulos, Vasso
[J]. IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161

← 1 2 3 4 5 →